Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

   Active, not recruiting · Phase 2 · Advanced Solid Tumor

   NCT06660654 · Daiichi Sankyo Inc. · 13 U.S. investigators

   $987,972research payments

2. Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

   Active, not recruiting · Phase 3 · Immunoglobulin A Nephropathy

   NCT05248646 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 40 U.S. investigators

   $986,657research payments

3. Candin for the Treatment of Common Warts

   Completed · Phase 3 · Common Warts (Verruca Vulgaris)

   NCT05889845 · Nielsen Biosciences, Inc. · 0 U.S. investigators

   $976,202research payments

4. Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

   Completed · Phase 1 · Autism Spectrum Disorder

   NCT06557902 · Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) · 5 U.S. investigators

   $975,033research payments

5. A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

   Completed · Phase 4 · Healthy Volunteers

   NCT06634797 · ModernaTX, Inc. · 24 U.S. investigators

   $972,458research payments

6. Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

   Active, not recruiting · Phase 2 · Non-Hodgkin's Lymphoma

   NCT03198026 · AbbVie Inc. · 1 U.S. investigator

   $967,584research payments

7. A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

   Completed · Phase 2 · Sepsis-Induced Hypotension

   NCT06608901 · Regeneron Pharmaceuticals, Inc. · 11 U.S. investigators

   $966,637research payments

8. A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

   Completed · Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps

   NCT06691113 · Sanofi US Services Inc. · 10 U.S. investigators

   $965,827research payments

9. Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

   Recruiting · Phase 1 · Advanced Solid Tumor Cancer

   NCT04777994 · AbbVie Inc. · 17 U.S. investigators

   $964,459research payments

10. REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

    Recruiting · Phase 3 · Venous Thromboembolism (VTE)

    NCT07015905 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $962,840research payments

11. A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

    Recruiting · Phase 1, Phase 2 · Relapsed/Refractory Systemic Light Chain Amyloidosis

    NCT06292780 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

    $962,452research payments

12. Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

    Terminated · Phase 3 · Tuberous Sclerosis Complex

    NCT05604170 · Immedica Pharma US, Inc. · 31 U.S. investigators

    $961,192research payments

13. A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

    Completed · Phase 2, Phase 3 · Bullous Pemphigoid

    NCT04206553 · Regeneron Pharmaceuticals, Inc. · 15 U.S. investigators

    $960,052research payments

14. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Recruiting · Pulmonary Hypertension Due to Lung Diseases and Hypoxia

    NCT06388421 · United Therapeutics Corporation · 46 U.S. investigators

    $958,166research payments

15. Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT06233942 · Beone Medicines Ltd. · 5 U.S. investigators

    $957,579research payments

16. A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

    Completed · Phase 2 · Alzheimer Disease

    NCT05063539 · Eli Lilly and Company · 37 U.S. investigators

    $956,554research payments

17. Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

    Active, not recruiting · Not applicable · Coronary Artery Disease

    NCT03108456 · Abbott Laboratories · 66 U.S. investigators

    $954,002research payments

18. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

    Recruiting · Phase 1, Phase 2 · Advanced Solid Tumors

    NCT05533697 · ModernaTX, Inc. · 12 U.S. investigators

    $949,134research payments

19. Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)

    Active, not recruiting · Not applicable · Peripheral Neuralgia

    NCT05870124 · Nalu Medical, Inc. · 17 U.S. investigators

    $947,819research payments

20. A Study of LY4005130 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06690996 · Eli Lilly and Company · 1 U.S. investigator

    $943,072research payments

21. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Recruiting · Phase 3 · Non Small Cell Lung Cancer

    NCT04928846 · AbbVie Inc. · 38 U.S. investigators

    $942,069research payments

22. A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

    Active, not recruiting · Phase 2 · Lupus Erythematosus, Systemic

    NCT07015983 · E.r. Squibb & Sons, L.l.c. · 14 U.S. investigators

    $936,412research payments

23. A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

    Completed · Phase 3 · Allergic Conjunctivitis

    NCT06602726 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $934,935research payments

24. A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

    Completed · Phase 1 · Healthy Participants

    NCT06716879 · UCB SA · 1 U.S. investigator

    $934,495research payments

25. Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Active, not recruiting · Phase 2, Phase 3 · Non-Small Cell Lung Cancer

    NCT06236438 · AbbVie Inc. · 18 U.S. investigators

    $933,084research payments

26. Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age

    Completed · Not applicable · Periodontal Disease

    NCT06582056 · Sanofi US Services Inc. · 4 U.S. investigators

    $932,326research payments

27. Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

    Terminated · Phase 2 · Asthma

    NCT06033833 · Sanofi US Services Inc. · 9 U.S. investigators

    $928,258research payments

28. A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

    Terminated · Phase 1 · Major Depressive Disorder (MDD)

    NCT06618118 · AbbVie Inc. · 6 U.S. investigators

    $927,392research payments

29. Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

    Active, not recruiting · Phase 1 · Recurrent Mantle Cell Lymphoma

    NCT02159755 · AbbVie Inc. · 1 U.S. investigator

    $927,268research payments

30. (VELA) Study of BLU-222 in Advanced Solid Tumors

    Terminated · Phase 1 · Advanced Solid Tumors

    NCT05252416 · Sanofi US Services Inc. · 19 U.S. investigators

    $919,074research payments

31. Assessment of CCM in HF With Higher Ejection Fraction

    Recruiting · Not applicable · Heart Failure

    NCT05064709 · Impulse Dynamics (USA) Inc. · 74 U.S. investigators

    $915,340research payments

32. Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

    Completed · Phase 1 · Hypertrophic Cardiomyopathy

    NCT02329184 · E.r. Squibb & Sons, L.l.c. · 23 U.S. investigators

    $915,244research payments

33. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

    Active, not recruiting · Phase 3 · Generalized Myasthenia Gravis

    NCT05070858 · Regeneron Pharmaceuticals, Inc. · 14 U.S. investigators

    $911,638research payments

34. A Study of Baricitinib in Participants With Rheumatoid Arthritis

    Completed · Phase 4 · Rheumatoid Arthritis

    NCT04086745 · Eli Lilly and Company · 75 U.S. investigators

    $910,722research payments

35. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

    Completed · Phase 1 · Healthy

    NCT06132126 · Eli Lilly and Company · 3 U.S. investigators

    $907,648research payments

36. Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

    Completed · Phase 3 · Primary Progressive Multiple Sclerosis

    NCT04458051 · Genzyme Corporation · 35 U.S. investigators

    $905,220research payments

37. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

    Terminated · Phase 1, Phase 2 · Multiple Myeloma

    NCT03215030 · Takeda Pharmaceuticals U.S.A., Inc. · 17 U.S. investigators

    $903,767research payments

38. An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

    Terminated · Phase 2 · Parkinson's Disease

    NCT05543252 · UCB SA · 43 U.S. investigators

    $899,812research payments

39. A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

    Active, not recruiting · Phase 2 · Ulcerative Colitis

    NCT06598943 · Eli Lilly and Company · 38 U.S. investigators

    $891,548research payments

40. A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    Completed · Phase 1 · Advanced Solid Tumor

    NCT06422520 · Beone Medicines USA, Inc. · 5 U.S. investigators

    $891,392research payments

41. A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

    Completed · Phase 1, Phase 2 · Influenza

    NCT05972174 · ModernaTX, Inc. · 9 U.S. investigators

    $889,740research payments

42. myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

    Recruiting · Not applicable · COPD

    NCT05204888 · Fisher & Paykel Healthcare Limited · 1 U.S. investigator

    $876,000research payments

43. A Study of Lu AF82422 in Participants With Multiple System Atrophy

    Active, not recruiting · Phase 2 · Multiple System Atrophy

    NCT05104476 · H. Lundbeck A S · 14 U.S. investigators

    $866,957research payments

44. NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

    Active, not recruiting · Phase 2 · Advanced Biliary Tract Cancer

    NCT04005339 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $866,372research payments

45. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

    Active, not recruiting · Phase 1, Phase 2 · Open-angle Glaucoma

    NCT04499248 · AbbVie Inc. · 29 U.S. investigators

    $861,717research payments

46. EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

    Enrolling by invitation · Not applicable · Heart Failure

    NCT05610787 · Berlin Heart Inc · 11 U.S. investigators

    $859,620research payments

47. A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

    Terminated · Phase 1, Phase 2 · Acute Myeloid Leukemia

    NCT06508489 · Sanofi US Services Inc. · 6 U.S. investigators

    $855,677research payments

48. A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

    Active, not recruiting · Phase 1 · Breast Cancer

    NCT04188548 · Eli Lilly and Company · 21 U.S. investigators

    $855,370research payments

49. Evaluation of the GORE® Ascending Stent Graft

    Enrolling by invitation · Not applicable · Aortic Aneurysm, Thoracic

    NCT05800743 · W. L. Gore & Associates, Inc. · 23 U.S. investigators

    $849,901research payments

50. Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

    Active, not recruiting · Phase 2 · CCND1 Positive

    NCT01880567 · AbbVie Inc. · 1 U.S. investigator

    $846,636research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.